M
Mercedes E. Gorre
Researcher at Quest Diagnostics
Publications - 38
Citations - 6629
Mercedes E. Gorre is an academic researcher from Quest Diagnostics. The author has contributed to research in topics: Myeloid leukemia & Imatinib mesylate. The author has an hindex of 20, co-authored 38 publications receiving 6473 citations. Previous affiliations of Mercedes E. Gorre include University of California & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
Mercedes E. Gorre,Mansoor Mohammed,Katharine Ellwood,Nicholas C. Hsu,Ron Paquette,P. Nagesh Rao,Charles L. Sawyers +6 more
TL;DR: It is found that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined and a strategy for identifying inhibitors of STI-571 resistance is suggested.
Journal ArticleDOI
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Neil P. Shah,John Nicoll,Bhushan Nagar,Mercedes E. Gorre,Ronald Paquette,John Kuriyan,John Kuriyan,Charles L. Sawyers +7 more
TL;DR: Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib are identified.
Journal ArticleDOI
BCR-ABL point mutants isolated from patients with imatinib mesylate–resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90
Mercedes E. Gorre,Katharine Ellwood-Yen,Katharine Ellwood-Yen,Gabriela Chiosis,Gabriela Chiosis,Neal Rosen,Neal Rosen,Charles L. Sawyers,Charles L. Sawyers +8 more
TL;DR: Clinical data support clinical investigations of 17-AAG in imatinib mesylate-resistant Ph(+) leukemias, with a trend indicating more potent activity against mutant BCR-ABL proteins.
Journal ArticleDOI
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Sergei Roumiantsev,Neil P. Shah,Mercedes E. Gorre,John Nicoll,Bradley B. Brasher,Charles L. Sawyers,Richard A. Van Etten +6 more
TL;DR: Because clinical resistance induced by the Y253F mutation might be overcome by dose escalation of STI-571, molecular genotyping of STi-571-resistant patients may provide information useful for rational therapeutic management.
Journal ArticleDOI
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Brian J. Skaggs,Mercedes E. Gorre,Ann Ryvkin,Michael R. Burgess,Yongming Xie,Yun Han,Evangelia Komisopoulou,Lauren M. Brown,Joseph A. Loo,Elliot M. Landaw,Charles L. Sawyers,Thomas G. Graeber +11 more
TL;DR: In this article, the authors evaluated the oncogenicity of eight kinase inhibitor-resistant BCR-ABL mutants and found a spectrum of potencies greater or less than p210.